776 |
CALCIUM VOLTAGE-GATED CHANNEL SUBUNIT ALPHA1 D |
CACNA1D |
CACH3 |
CACN4 |
CACNL1A2 |
CCHL1A2 |
Cav1.3 |
PASNA |
SANDD |
114206 |
1391 |
ENSG00000157388 |
OTTHUMG00000158278 |
Voltage-gated calcium channel subunit alpha Cav1.3 |
Voltage-dependent L-type calcium channel subunit alpha-1D |
Calcium channel, L type, alpha-1 polypeptide, isoform 2 |
CAC1D_HUMAN |
Q01668 |
PA84 |
VOLTAGE-DEPENDENT L-TYPE CALCIUM CHANNEL ALPHA-1D SUBUNIT (VOLTAGE- GATED CALCIUM CHANNEL ALPHA SUBUNIT CAV1.3) (CALCIUM CHANNEL, L TYPE, ALPHA-1 POLYPEPTIDE, ISOFORM 2). [SOURCE:UNIPROT/SWISSPROT;ACC:Q01668] |
Voltage-gated calcium channel alpha Cav1.3 |
T24793 |
Target Subclass | CalciumChannels |
Target Subclass | Channels |
Transmembrane Helix Count | 19 |
Target Subclass | Voltage_gated_ion_channels |
Target Main Class | Transporters |
Initial Gene Query | Cav1.3 |
Counted Citations from 1950-2000 | 463 |
Interpro Type | Domain |
Interpro Name | Ion transport domain |
Human Readable Name | ION CHANNEL |
Uniprot Status | Swiss-Prot |
Interpro Short Name | Ion_trans_dom |
Human Readable Name | DRUGGABLE GENOME |
Interpro Acc | IPR005821 |
Uniprot Evidence | 1: Evidence at protein level |
Target Class | Transporters |
Target Subclass | TC:1.A.1.11 |
Gene Biotype | PROTEIN_CODING |
ION CHANNEL |
DRUGGABLE GENOME |
CLINICALLY ACTIONABLE |
blocker (inhibitory) |
Trial Name | Clevelox |
Novel drug target | Established target |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
blocker (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
blocker (inhibitory) |
inhibitor (inhibitory) |
Trial Name | enalapril + felodipine,Lexxel |
Novel drug target | Established target |
Trial Name | felodipine ,Plendil |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | aliskiren + amlodipine,Tekamlo |
Novel drug target | Established target |
Trial Name | amlodipine besylate,Norvasc |
blocker (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
blocker (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
blocker (inhibitory) |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | Verapamil,Calan, Covera-HS |
blocker (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated calcium channel blocker |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
CACNA1D | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
VOLTAGE-DEPENDENT L-TYPE CALCIUM CHANNEL SUBUNIT ALPHA-1D | Uniprot Protein Name |
CAC1D_HUMAN | Uniprot Id |
ENSG00000157388 | Ensembl Gene Id |
Interpro Type | Domain |
Interpro Name | Ion transport domain |
Human Readable Name | ION CHANNEL |
ION CHANNEL, DRUGGABLE GENOME |
CACNA1D | Gene Symbol |
Target Class | Transporters |
Target Subclass | TC:1.A.1.11 |
ENSG00000157388 | Ensembl Gene Id |
VOLTAGE-DEPENDENT L-TYPE CALCIUM CHANNEL ALPHA-1D SUBUNIT (VOLTAGE- GATED CALCIUM CHANNEL ALPHA SUBUNIT CAV1.3) (CALCIUM CHANNEL, L TYPE, ALPHA-1 POLYPEPTIDE, ISOFORM 2). [SOURCE:UNIPROT/SWISSPROT;ACC:Q01668] | Description |
CACNA1D | Display Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
ENSG00000157388 | Ensembl Gene Id |
776 | Entrez Gene Id |
CACNA1D | Gene Symbol |
Target Subclass | CalciumChannels |
Target Subclass | Channels |
Transmembrane Helix Count | 19 |
776 | Entrez Gene ID |
Initial Gene Query | Cav1.3 |
Counted Citations from 1950-2000 | 463 |
ION CHANNEL |
PA84 | PharmGKB ID |
ENSG00000157388 | Gene Symbol |
CACNA1D | Ensembl Id |
DRUGGABLE GENOME |
CACN4 | GENE_SYMBOL |
CACNL1A2 | GENE_SYMBOL |
CCHL1A2 | GENE_SYMBOL |
CACNA1D | TTD Gene Abbreviation |
T24793 | TTD Target ID |
Voltage-dependent L-type calcium channel subunit alpha-1D | Gene Name |
Q01668 | UniProt ID |
ION CHANNEL |
CLINICALLY ACTIONABLE |